13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 4 of 6 – SEC Filing

 

CUSIP
No. 253031108

 

1

Names of Reporting Persons.

RA Capital Healthcare Fund, L.P.

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

WC

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6 Citizenship or Place of Organization.     Delaware

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7
Sole Voting Power     0
8
Shared Voting Power      3,446,728
9
Sole Dispositive Power     0
10
Shared Dispositive Power  3,446,728
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

3,446,728

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
13

Percent of Class Represented by Amount
in Row (11)

6.7%3

14

Type of Reporting Person (See Instructions)

PN (Limited Partnership)

3
Represents 3,446,728 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc.
(the “Issuer”) which constitutes approximately 6.7% of the class outstanding. The percentage calculation assumes that
there are currently 51,766,999 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-K as
filed with the Securities and Exchange Commission (“SEC”) on March 8, 2018.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)